Q3: 2025-11-05 Earnings Summary
EPS of -$1.61 misses by $0.20
| Revenue of $0.00 misses by $1.49M
Revolution Medicines, Inc. (RVMD) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 9:00 AM EST
Company Participants
Mark Goldsmith - CEO, President & Chairman
Conference Call Participants
Michael Schmidt - Guggenheim Securities, LLC, Research Division
Presentation
Michael Schmidt Guggenheim Securities, LLC, Research Division
All right. So we’ll get started right away. So I’d like to welcome Mark Goldsmith for the next fireside chat here, President and CEO of Re…
Q3: 2025-11-05 Earnings Summary
EPS of -$1.61 misses by $0.20
| Revenue of $0.00 misses by $1.49M
Revolution Medicines, Inc. (RVMD) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 9:00 AM EST
Company Participants
Mark Goldsmith - CEO, President & Chairman
Conference Call Participants
Michael Schmidt - Guggenheim Securities, LLC, Research Division
Presentation
Michael Schmidt Guggenheim Securities, LLC, Research Division
All right. So we’ll get started right away. So I’d like to welcome Mark Goldsmith for the next fireside chat here, President and CEO of Revolution Medicines. Mark, welcome. Thanks for joining us.
Question-and-Answer Session
Michael Schmidt Guggenheim Securities, LLC, Research Division
So we’ll jump right into Q&A. So obviously, an exciting time for the company with pivotal studies underway for daraxonrasib, more to come. And so just jumping right into a question.
Your most advanced registration study is the second-line pancreatic cancer trial, RASolute 302, that’s ongoing and nearing completion of enrollment. And yes, as we look forward to the first registration data disclosure next year. The Phase II data was obviously very promising. What have you done to ensure that the Phase II data translates into the Phase III study?
Mark Goldsmith CEO, President & Chairman
Yes. Thanks for the question. I think that we found that the patient population in our Phase I/II trial was very similar to the populations that have been studied in a variety of Phase III trials in pancreatic cancer, very consistent across the board. We really didn’t find a risk profile that differed much. If anything, the patients in the Phase I/II trial were slightly worse off, had worse prognostic factors than those in conventional Phase III trials that have been reported. So I think on that basis, we would assume that we had a representative population and therefore, would expect it to be relatively similar in the Phase III trial.
Michael Schmidt Guggenheim Securities, LLC, Research